Abstract
Treatment of locally advanced and metastatic prostate cancer (PC) with androgen receptor–targeting (AR-targeting) therapies has limited durability, with disease eventually progressing to castrate-resistant PC (CRPC). Constitutively active AR splice variants (AR-Vs), such as AR-V7, play a key role in driving treatment resistance and disease progression. Importantly, the failure to attenuate AR-V function represents a major unmet clinical need, and as such, defining how AR-Vs are generated is likely to yield new therapeutic targets. Our knowledge of factors that mediate splicing of AR-V–encoding mRNAs remains limited. Here, we have employed an RNA-targeting CasRx approach to identify selective protein interactors of AR-V7 mRNA in PC. TRA2B and its ortholog, TRA2A, were identified as splicing regulators of AR transcripts that facilitate AR-V synthesis at the expense of full-length AR isoforms. TRA2B expression correlated with AR-V7 transcript in CRPC and attenuation of TRA2-mediated splicing diminished PC cell growth. Exploiting TRA2B function may therefore provide new therapeutic opportunities in advanced disease.
Funding Information
  • Prostate Cancer UK (CEO13_2-002)
  • Prostate Cancer Foundation (18CHAL06,20YOUN17)
  • Cancer Research UK (CTRQQR-2021\100009)
  • Experimental Cancer Medicine Centre (N/A)
  • Wellcome Trust (219594/Z/19/Z)
  • Cancer Research UK (C9380/A25138)
  • Ken Bell Bursary and JGW Patterson Foundation (12/21 NU009331)
  • Prostate Cancer Research (PCR-6955)
  • National Institute for Health and Care Research (NIHR205032)

This publication has 76 references indexed in Scilit: